ArticleGland surgery2026
Comprehensive comparisons of total pancreatectomy versus pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a double-center, retrospective study.
Article in Gland surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Total pancreatectomy (TP) is necessary in some cases to treat pancreatic cancer. However, TP is still controversial due to its unsatisfactory short- and long-term clinical outcomes previously. This study aimed to compare the perioperative outcomes, long-term survival and quality of life (QoL) between TP and the widely recognized pancreaticoduodenectomy (PD) in patients with pancreatic ductal adenocarcinoma (PDAC). Methods: A total of 68 patients with PDAC who underwent elective TP at Beijing Chao-Yang Hospital and Beijing Hospital from January 2021 to December 2023 were retrospectively reviewed. Another 68 patients receiving PD during the same time period were also randomly selected for comparison. Perioperative data were retrospectively reviewed. Survival status was recorded by regular follow-up, and the end date of follow-up was December 31, 2024. Questionnaires were sent to the survivors to evaluate their long-term endo-exocrine insufficiency and QoL. Results: No significant differences were found in postoperative morbidity, mortality or total hospitalization costs between the two groups, while the postoperative hospital stay of the TP group was even shorter (19 Conclusions: The TP procedure may be as safe, feasible and efficacious as PD with similar short- and long-term clinical outcomes for patients with PDAC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.